Amphastar Q2 Revenue Climbs 5% to $183.9M, GAAP EPS $0.67; BAQSIMI Milestone Triggers $100M Payment
AMPH sits 22% above its 52-week low of $16.645.
Summary
Amphastar's Q2 revenue rose 5% to $183.9M, but earnings dipped. A BAQSIMI sales milestone triggers a $100M payment to Lilly, while an FDA Warning Letter at its IMS plant adds regulatory risk.
Key Events · Earnings and Guidance · AMPH
-
Q2 Revenue Up 5%, Earnings Dip
Net revenues of $183.9M (+5% YoY) were driven by new products; GAAP EPS came in at $0.67 versus $0.64 a year ago, but net income fell 2% to $30.3M as operating expenses rose 21%.
-
BAQSIMI Milestone Triggers $100M Payment
BAQSIMI annual net sales reached $175M, triggering a $100M milestone payment to Eli Lilly due in Q3 2026 — a significant cash outflow that will reduce liquidity.
-
FDA Warning Letter at IMS Facility
Subsidiary IMS received an FDA Warning Letter for cGMP violations; remediation is underway, and management expects no material financial impact, but regulatory risk remains.
-
Strong Operating Cash Flow, Aggressive Buybacks
H1 2026 operating cash flow was $99.2M, but the company spent $74.7M on share repurchases, raising concerns about capital allocation ahead of the $100M milestone payment.
Analysis · AMPH · Life Sciences
Amphastar turned in a mixed quarter. Revenue grew 5% to $183.9 million, fueled by new product launches, but net income slipped 2% as operating expenses jumped 21% on higher R&D and legal costs. The standout development is the BAQSIMI sales milestone — hitting $175 million in annual sales triggers a $100 million payment to Eli Lilly due next quarter, a significant cash outflow that will pressure liquidity. Gross margins improved slightly, and the company generated strong operating cash flow of $99 million in the first half, yet aggressive share buybacks ($74.7 million) and the looming milestone payment raise questions about capital allocation. Adding to the overhang, the FDA Warning Letter at the IMS facility introduces regulatory risk, though management expects limited financial impact.
At the time of this filing, AMPH was trading at $20.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $873.5M. The 52-week trading range was $16.65 to $31.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.